Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ZIYAD A AYYOUB

Allopathic & Osteopathic Physicians Physical Medicine & Rehabilitation

NPI
1356451579
CMS profile
106399
Location
PARAMOUNT, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$47,457.15

68 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Ipsen Biopharmaceuticals, Inc $24,410.01 19
AbbVie Inc. $20,575.70 28
Pacira Pharmaceuticals Incorporated $884.58 7
MDD US Operations, LLC $880.00 1
Merz Pharmaceuticals, LLC $669.22 11
Novo Nordisk Inc $37.64 2

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ZIYAD A AYYOUB

NPI 1356451579 · CMS profile ID 106399

Allopathic & Osteopathic Physicians / Physical Medicine & Rehabilitation

PARAMOUNT, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356451579?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ZIYAD A AYYOUB, NPI 1356451579, CMS profile ID 106399. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356451579?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ZIYAD A AYYOUB, NPI 1356451579, CMS profile ID 106399. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356451579?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ZIYAD A AYYOUB, NPI 1356451579, CMS profile ID 106399, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–68 of 68 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356451579?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

68 matching records · $47,457.15 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 68 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–68 of 68.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Ipsen Biopharmaceuticals, Inc $80.0003/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405202 CMS
Ipsen Biopharmaceuticals, Inc $103.5403/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405213 CMS
Ipsen Biopharmaceuticals, Inc $359.0603/07/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405217 CMS
AbbVie Inc. $65.6402/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996181873 CMS
Ipsen Biopharmaceuticals, Inc $140.6002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405177 CMS
Merz Pharmaceuticals, LLC $172.4002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048295383 CMS
Merz Pharmaceuticals, LLC $75.0002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048295389 CMS
Merz Pharmaceuticals, LLC $8.3702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048295395 CMS
Merz Pharmaceuticals, LLC $24.6802/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048295401 CMS
AbbVie Inc. $1,440.0002/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996181869 CMS
AbbVie Inc. $1,440.0002/06/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996181871 CMS
Ipsen Biopharmaceuticals, Inc $588.5802/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405183 CMS
Ipsen Biopharmaceuticals, Inc $401.2002/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405187 CMS
Ipsen Biopharmaceuticals, Inc $1,053.2202/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405191 CMS
Ipsen Biopharmaceuticals, Inc $10,965.0002/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405207 CMS
Ipsen Biopharmaceuticals, Inc $588.5801/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405239 CMS
Ipsen Biopharmaceuticals, Inc $889.2701/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405245 CMS
Ipsen Biopharmaceuticals, Inc $401.2001/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045405259 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $76,364.90 141
PY2020 $28,366.05 34
PY2021 $62,466.39 47
PY2022 $47,015.54 48
PY2023 $47,457.15 68
PY2024 $37,561.37 65
PY2025 $22,398.76 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $293,303.57 37
PY2024 Recipient $1,496.08 3
PY2024 Principal investigator $137,960.95 20
PY2023 Principal investigator $454,865.66 3,730
PY2022 Principal investigator $442,815.76 192
PY2021 Principal investigator $94,380.75 320
PY2020 Principal investigator $7,100.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

37 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 12/18/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304981
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 12/18/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304985
Principal investigator 1 Pacira Pharmaceuticals Incorporated $262.00 12/16/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304963
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 12/12/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304978
Principal investigator 1 Pacira Pharmaceuticals Incorporated $2,944.26 11/26/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304974
Principal investigator 1 Pacira Pharmaceuticals Incorporated $2,944.26 11/25/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304941
Principal investigator 1 Merz Pharmaceuticals, LLC $4,151.60 11/17/2025 Non-covered Recipient Entity
Rancho Research Institute
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647492
Principal investigator 1 Merz Pharmaceuticals, LLC $35,733.76 11/17/2025 Non-covered Recipient Entity
Rancho Research Institute
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647494
Principal investigator 1 Pacira Pharmaceuticals Incorporated $524.00 11/14/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304998
Principal investigator 1 Pacira Pharmaceuticals Incorporated $13.16 11/04/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304954
Principal investigator 1 Pacira Pharmaceuticals Incorporated $17.32 10/30/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304946
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 10/21/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304950
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 10/16/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304939
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 10/16/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304959
Principal investigator 1 Pacira Pharmaceuticals Incorporated $32.90 09/17/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304968
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 09/05/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304994
Principal investigator 1 Pacira Pharmaceuticals Incorporated $981.42 08/13/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304989
Principal investigator 1 Ipsen Innovation $8,004.85 08/12/2025 Non-covered Recipient Entity
RANCHO RESEARCH INSTITUTE
An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity. No dispute reported 06/30/2026 1184286550
Principal investigator 1 Merz Pharmaceuticals, LLC $88,401.89 08/11/2025 Non-covered Recipient Entity
Rancho Research Institute
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647490
Principal investigator 1 Merz Pharmaceuticals, LLC $11,411.29 06/18/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647508
Principal investigator 1 Pacira Pharmaceuticals Incorporated $338.44 05/07/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304914
Principal investigator 1 Pacira Pharmaceuticals Incorporated $524.00 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304897
Principal investigator 1 Pacira Pharmaceuticals Incorporated $13.40 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304901
Principal investigator 1 Pacira Pharmaceuticals Incorporated $5,816.46 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304906
Principal investigator 1 Pacira Pharmaceuticals Incorporated $43.30 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304909
Principal investigator 1 Pacira Pharmaceuticals Incorporated $32.90 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304918
Principal investigator 1 Pacira Pharmaceuticals Incorporated $2,926.02 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304922
Principal investigator 1 Pacira Pharmaceuticals Incorporated $3,925.68 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304927
Principal investigator 1 Pacira Pharmaceuticals Incorporated $1,962.84 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304930
Principal investigator 1 Pacira Pharmaceuticals Incorporated $34.42 04/22/2025 Non-covered Recipient Entity
Rancho Research Institute
A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity No dispute reported 06/30/2026 1250304935
Principal investigator 1 Merz Pharmaceuticals, LLC $6,028.26 04/10/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647504
Principal investigator 1 Merz Pharmaceuticals, LLC $20,831.25 04/10/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647506
Principal investigator 1 ABBVIE INC. $5,250.00 03/18/2025 Non-covered Recipient Entity
RANCHO RESEARCH INSTITUTE INC
M23-499 - Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity No dispute reported 06/30/2026 1202464228
Principal investigator 1 Merz Pharmaceuticals, LLC $6,024.38 03/01/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647500
Principal investigator 1 Merz Pharmaceuticals, LLC $2,547.01 02/17/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647498
Principal investigator 1 Merz Pharmaceuticals, LLC $40,652.50 02/10/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647502
Principal investigator 1 Merz Pharmaceuticals, LLC $30,134.38 01/06/2025 Non-covered Recipient Entity
Rancho Research Institute at Rancho Los Amigos National Rehabilitation Center
Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of NT 201 in the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury in Adult Subjects, Followed by an Open Label Extension With or Without Combined Upper Limb Treatment No dispute reported 06/30/2026 1232647496